Creative Planning Buys 49,890 Shares of Progenics Pharmaceuticals, Inc. (PGNX)

Creative Planning grew its stake in shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) by 23.9% in the third quarter, according to its most recent filing with the SEC. The fund owned 258,600 shares of the biotechnology company’s stock after acquiring an additional 49,890 shares during the period. Creative Planning owned about 0.31% of Progenics Pharmaceuticals worth $1,621,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the company. Northern Trust Corp increased its holdings in shares of Progenics Pharmaceuticals by 6.8% in the second quarter. Northern Trust Corp now owns 934,820 shares of the biotechnology company’s stock valued at $7,516,000 after purchasing an additional 59,558 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Progenics Pharmaceuticals by 2.3% in the second quarter. Bank of New York Mellon Corp now owns 1,062,981 shares of the biotechnology company’s stock valued at $8,546,000 after purchasing an additional 24,073 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Progenics Pharmaceuticals by 312.3% in the second quarter. Millennium Management LLC now owns 119,350 shares of the biotechnology company’s stock valued at $960,000 after purchasing an additional 90,400 shares in the last quarter. Raymond James & Associates increased its holdings in shares of Progenics Pharmaceuticals by 24.3% in the second quarter. Raymond James & Associates now owns 71,586 shares of the biotechnology company’s stock valued at $576,000 after purchasing an additional 14,008 shares in the last quarter. Finally, Employees Retirement System of Texas increased its holdings in shares of Progenics Pharmaceuticals by 21.9% in the second quarter. Employees Retirement System of Texas now owns 139,000 shares of the biotechnology company’s stock valued at $1,118,000 after purchasing an additional 25,000 shares in the last quarter. Institutional investors own 76.45% of the company’s stock.

Shares of Progenics Pharmaceuticals stock opened at $5.01 on Thursday. The company has a debt-to-equity ratio of 0.68, a current ratio of 6.34 and a quick ratio of 6.34. The company has a market capitalization of $418.48 million, a P/E ratio of -5.57 and a beta of 2.49. Progenics Pharmaceuticals, Inc. has a fifty-two week low of $4.68 and a fifty-two week high of $9.42.

Progenics Pharmaceuticals (NASDAQ:PGNX) last issued its quarterly earnings results on Tuesday, July 31st. The biotechnology company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02). Progenics Pharmaceuticals had a negative net margin of 341.41% and a negative return on equity of 94.45%. The company had revenue of $3.88 million during the quarter, compared to analyst estimates of $3.30 million. Equities analysts predict that Progenics Pharmaceuticals, Inc. will post -0.67 earnings per share for the current fiscal year.

A number of analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 4th. ValuEngine raised shares of Progenics Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, July 30th. Jefferies Financial Group reissued a “buy” rating and issued a $13.00 price target on shares of Progenics Pharmaceuticals in a report on Wednesday, August 1st. BidaskClub lowered shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, September 5th. Finally, Needham & Company LLC reissued a “strong-buy” rating and issued a $14.00 price target on shares of Progenics Pharmaceuticals in a report on Wednesday, August 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. Progenics Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $11.69.

About Progenics Pharmaceuticals

Progenics Pharmaceuticals, Inc develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer.

See Also: What is the Dividend Aristocrat Index?

Institutional Ownership by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply